Antiplatelet therapy for patients with acute coronary syndrome and chronic kidney disease after percutaneous coronary intervention
10.3969/j.issn.1004-8812.2023.11.010
- VernacularTitle:急性冠状动脉综合征合并慢性肾病患者介入术后双联抗血小板治疗的研究进展
- Author:
Jing-Da CUI
1
;
Jiang-Li HAN
Author Information
1. 100191 北京,北京大学第三医院心内科;100191 北京,北京大学第三医院全科医学科
- Keywords:
Acute coronary syndrome;
Chronic kidney disease;
Antiplatelet therapy
- From:
Chinese Journal of Interventional Cardiology
2023;31(11):867-871
- CountryChina
- Language:Chinese
-
Abstract:
Aspirin combined with P2Y12 receptor inhibitors is the standard dual antiplatelet therapy for the prevention of stent thrombosis and systemic atherosclerotic thrombotic events after percutaneous coronary intervention in acute coronary syndrome(ACS).Patients with ACS combined with chronic kidney disease(CKD)have a higher risk of thrombosis and a higher incidence of bleeding.Therefore,it is important to determine the optimal antiplatelet therapy strategy for this population.Most clinical trials have excluded patients with advanced CKD,so clinicians lack evidence-based medical evidence for antiplatelet therapy strategies in these patients.This article reviews the research progress of antiplatelet therapy in ACS patients with CKD,in order to provide reference for clinicians to choose appropriate antiplatelet therapy strategies when facing such patients.
